R&D SPENDING - Higher research and development expenses mainly due to increased manufacturing, clinical, and regulatory consulting costs for GPS program
ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher professional fees and non-cash stock-based compensation
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Sellas Life Sciences Group Inc is $27.50, about 149.1% above its August 10 closing price of $11.04
Quarterly results and cash position
US biopharma firm's Q2 net loss widened yr/yr as operating expenses increased
SLS•
